🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The 10th publication from the iStopMM study, published in Nature Medicine in 2023, defines for the first time the prevalence of smoldering multiple myeloma (SMM) in the general population. 📊🩸 #iStopMM #MultipleMyeloma Sigrun Thorsteinsdottir

CTX or MTX for LGL library.ehaweb.org/eha/2025/eha20…

Wow…I didn’t expect that

Cuando dos grandes se encuentran…

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders ashpublications.org/bloodadvances/… Important work by Pau Abrisqueta

Interesting study…geriatric assessments are important but not always feasible.. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: astctjournal.org/article/S2666-…

Amazing results of rusfertide for PV. Congratulations Andrew Kuykendall MD

Not a transplanter but definitely this is huge!

Burnout in Heme: relevant findings..

When maximum dose is not necessarily the most effective dose

Ibrutinib for RR PCNSL and SCNSL…COO, PS and MYD88 expression affect outcomes #icml2025 GELTAMO

PET parameters at baseline and d30 impact outcomes in LBCL after CART #ICML2025

TCHR DLBCL and outcomes either antiCD19 CART no very good outcomes what is there anything else available? PD-1 inhibition did not affect outcomes DESCAR-T Lysa Lymphoma

PMBCL outcomes..large database Me he convertido en hincha de GELTAMO !

Another interesting study from GELTAMO R-mono & RCHOP have similar outcomes in PTLD. Largest database I’ve seen. Wonder whether rituximab refractory impact outcomes

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

While #Lugano was taking place interesting studies were presented elsewhere #ISTH2025 Apixiban Vs Rivaroxaban…

Interesting news for CART therapies: REMS no longer required fda.gov/vaccines-blood…

🩸Iron Deficiency for the Practicing Oncologist JCO Oncology Practice ✅A very useful excellent review 👉ascopubs.org/doi/pdf/10.120… ASCO #cancer #oncology #MedX OncoAlert Top Biomedical Science Top Science

Interesting editorial about second myeloid malignancies after CART